Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors

被引：0
|
作者：
Karima Saboundji
Jean-Bernard Auliac
Maurice Pérol
Géraldine François
Henri Janicot
Marie Marcq
Catherine Dubos-Arvis
Aldo Renault
Florian Guisier
Luc Odier
Radj Gervais
Christos Chouaïd
机构：
[1] CH François-Quesnay,Pneumologie et Oncologie Thoracique
[2] Centre Léon-Bérard,Oncologie
[3] CHU d’Amiens,Pneumologie et Oncologie Thoracique
[4] CHU Clermont-Ferrand,Pneumologie
[5] CHU Vendée,Pneumologie
[6] Centre François-Baclesse,Oncologie
[7] CH François-Mitterrand,Pneumologie
[8] CHU Charles-Nicolle,Pneumologie
[9] Hôpital Nord-Ouest,Pneumologie
[10] CH Intercommunal de Créteil,Pneumologie
来源：
Targeted Oncology | 2018年 / 13卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：501 / 507
页数：6
相关论文
共 50 条
  • [41] Small cell transformation in EGFR-mutated non-small cell lung cancer (EGFR plus NSCLC): Efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with platinum-based chemotherapy
    Saalfeld, F. C.
    Moeller, J.
    Michels, S.
    Grohe, C.
    Wiesweg, M.
    Schubart, C.
    Alt, J.
    Griesinger, F.
    Kauffmann-Guerrero, D.
    Kulhavy, J.
    Overbeck, T. R.
    Pelusi, N.
    Rohde, G.
    Wesseler, C.
    Vathiotis, I.
    Veluswamy, R.
    Illini, O. M.
    Rothschild, S. I.
    Christopoulos, P.
    Wermke, M.
    ANNALS OF ONCOLOGY, 2023, 34
  • [42] Advancing leptomeningeal metastases treatment in EGFR-mutated non-small cell lung cancer: lessons from the BLOSSOM trial
    Bortolot, Martina
    Huijs, Jarno W. J.
    Brandsma, Dieta
    Compter, Annette
    van Geel, Robin M. J. M.
    Hendriks, Lizza E. L.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2025, 14 (01) : 7 - 13
  • [43] Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors
    Liao, Bin-Chi
    Bai, Ya-Ying
    Lee, Jih-Hsiang
    Lin, Chia-Chi
    Lin, Shu-Yung
    Lee, Yee-Fan
    Ho, Chao-Chi
    Shih, Jin-Yuan
    Chang, Yeun-Chung
    Yu, Chong-Jen
    Yang, James Chih-Hsin
    Yang, Pan-Chyr
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2018, 117 (04) : 326 - 331
  • [44] Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis
    Miyawaki, Taichi
    Kenmotsu, Hirotsugu
    Yabe, Michitoshi
    Kodama, Hiroaki
    Nishioka, Naoya
    Miyawaki, Eriko
    Mamesaya, Nobuaki
    Kobayashi, Haruki
    Omori, Shota
    Wakuda, Kazushige
    Ono, Akira
    Deguchi, Shoichi
    Mitsuya, Koichi
    Naito, Tateaki
    Murakami, Haruyasu
    Mori, Keita
    Harada, Hideyuki
    Hayashi, Nakamasa
    Takahashi, Kazuhisa
    Takahashi, Toshiaki
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (06) : 1732 - 1741
  • [45] Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis
    Taichi Miyawaki
    Hirotsugu Kenmotsu
    Michitoshi Yabe
    Hiroaki Kodama
    Naoya Nishioka
    Eriko Miyawaki
    Nobuaki Mamesaya
    Haruki Kobayashi
    Shota Omori
    Kazushige Wakuda
    Akira Ono
    Shoichi Deguchi
    Koichi Mitsuya
    Tateaki Naito
    Haruyasu Murakami
    Keita Mori
    Hideyuki Harada
    Nakamasa Hayashi
    Kazuhisa Takahashi
    Toshiaki Takahashi
    Investigational New Drugs, 2021, 39 : 1732 - 1741
  • [46] Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01
    Hibino, Makoto
    Imamura, Yoshinori
    Shimoyama, Rai
    Fukui, Tomoya
    Fukai, Ryuta
    Iwase, Akihiko
    Tamura, Yukihiro
    Chihara, Yusuke
    Okabe, Takafumi
    Uryu, Kiyoaki
    Okuda, Tadahisa
    Taguri, Masataka
    Minami, Hironobu
    TARGETED ONCOLOGY, 2024, 19 (06) : 925 - 939
  • [47] Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
    Jiang, Tao
    Xu, Xiaobo
    Chen, Xiaojuan
    Ding, Ning
    Hu, Qin
    Zhou, Caicun
    Hu, Jie
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (06) : 2514 - 2517
  • [48] Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer
    Thompson, Jonathan R.
    Menon, Smitha P.
    Dy, Grace K.
    ADMET AND DMPK, 2016, 4 (03): : 186 - 211
  • [49] Genomic characterisation of de novo EGFR copy number gain and its impact on the efficacy of first-line EGFR-tyrosine kinase inhibitors for EGFR mutated non-small cell lung cancer
    Xu, Yiquan
    Yan, Jingjing
    Zhou, Chengzhi
    Wu, Lin
    Wang, Haibo
    Zhao, Jun
    Zhou, Maolin
    Wang, Jingyi
    Zheng, Xinlong
    Zhang, Longfeng
    Jiang, Kan
    Zheng, Xiaobin
    Miao, Qian
    Wu, Shiwen
    Zou, Zihua
    Lian, Rong
    He, Yuange
    Chen, Rongrong
    Yang, Shanshan
    Li, Yujing
    Chen, Sihui
    Lin, Gen
    EUROPEAN JOURNAL OF CANCER, 2023, 188 : 81 - 89
  • [50] Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer: A Meta-Analysis of 13 Randomized Trials
    Petrelli, Fausto
    Borgonovo, Karen
    Cabiddu, Mary
    Barni, Sandro
    CLINICAL LUNG CANCER, 2012, 13 (02) : 107 - 114
12345